Clinical trials: Infliximab
- Drug or intervention Infliximab
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of maintenance treatment with 3mg/kg, 6mg/kg or 10mg/kg of TA-650 in combination with methotrexate (MTX) after three infusions (weeks-0, 2, 6) of…
- Trial name
- NCT00691028
- Testing
- TA-650 3 mg/kg, TA-650 6 mg/kg, TA-650 10 mg/kg
- Volunteers
- 327 people
- Sponsor
- Tanabe Pharma Corporation
Crohn's Disease
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5…
- Trial name
- NCT00805766
- Testing
- TA-650
- Where
- 4 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Tanabe Pharma Corporation
Pediatric Crohn's Disease
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
The purpose of this study is to evaluate the efficacy of TA-650 using Pediatric Crohn's Disease Activity Index (PCDAI) in pediatric patients with moderate to severe Crohn's disease after TA-650 administration at a dose of 5 mg/kg…
- Trial name
- NCT01580670
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Tanabe Pharma Corporation
Rheumatoid Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.
- Trial name
- NCT03885037
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 77 people
- Sponsor
- Pfizer
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Crohn's Disease, Ulcerative Colitis
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Trial name
- NCT03884439
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 428 people
- Sponsor
- Pfizer
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Inflammatory Bowel Diseases
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
The purpose of this study is to evaluate whether trough serum infliximab concentrations at the time of loss of clinical response will identify pediatric participants with inflammatory bowel disease (IBD) who would benefit (regain…
- Trial name
- ADAPT (NCT02566889)
- Testing
- Infliximab
- Where
- 36 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Janssen Scientific Affairs, LLC
Arthritis, Rheumatoid
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.
- Trial name
- NCT05375942
- Testing
- Inflectra
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Pfizer
Crohn's Disease
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03945019
- Testing
- CT-P13 SC (Infliximab)
- Where
- 29 sites in United States, Belarus and 24 more
- Volunteers
- 396 people
- Sponsor
- Celltrion
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not…
- Trial name
- NCT02990806
- Testing
- NI-071, Remicade
- Where
- 134 sites in United States, Czechia and 6 more
- Volunteers
- 683 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to…
- Trial name
- GARDENIA (NCT02136069)
- Testing
- Etrolizumab, Infliximab
- Where
- 119 sites in Austria, Belgium and 18 more
- Volunteers
- 397 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD)
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
- Trial name
- ONWARD (NCT03801928)
- Testing
- Inflectra
- Where
- 15 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA.
- Trial name
- NCT00808210
- Testing
- Infliximab, Methotrexate, Methylprednisolone
- Where
- 53 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Crohn's Disease, Ulcerative Colitis (Part 2 Only)
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
Phase 1 randomized, open-label, multicenter, parallel-group study designed to evaluate efficacy, pharmacokinetics and safety between CT-P13 subcutaneous (SC) and CT-P13 intravenous (IV) in patients with active Crohn's Disease…
- Trial name
- NCT02883452
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 181 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion